Biochemical prevention and treatment of viral infections - A new paradigm in medicine for infectious diseases

Virology Journal

Volumn 1, Issue , 2004, Pages

  Le Calvez, Hervé ^a   Yu, Mang ^b   Fang, Fang ^b  

^a Abgent Inc   (United States)

^b NexBio Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; AVI 4126; AVI 4557; CFY 196; CIVACIR; CYTOLIN; DENUFOSOL; EPI 2010; FOMIVIRSEN; GENE EXPRESSION MODULATOR 231; GENE EXPRESSION MODULATOR 92; GTI 2040; GTI 2051; HEPATITIS B ANTIBODY; HNM 01; IF7 ANTIBODY; INS 372217; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; ISIS 104838; ISIS 14803; ISIS 2503; MEDI 491; MEDI 501; MG 98; MONOCLONAL ANTIBODY; NUMAX; OBLIMERSEN; ORAQUICK HIV 1; OSTAVIR; PALIVIZUMAB; PRO 140; PRO 367; RECOMBINANT ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RIBOZYME; SIS 3521; TIPRANAVIR; TNX 355; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS MESSENGER RNA; XTL 002;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; ASTHMA; CANCER; CLINICAL TRIAL; COMMON COLD; CONDYLOMA; CROHN DISEASE; DRUG EFFICACY; HEPATITIS B; HEPATITIS C; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; KIDNEY POLYCYSTIC DISEASE; PSORIASIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESTENOSIS; RETINITIS; RHEUMATOID ARTHRITIS; RNA INTERFERENCE; SOLID TUMOR; ULCERATIVE COLITIS; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BIOMEDICAL RESEARCH; HUMANS; VIRUS DISEASES; VIRUS REPLICATION;

EID: 15544374434     PISSN: 1743422X     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-1-12     Document Type: Article

References (51)

1. Anderson LJ, Bingham P, Hierholzer J: Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. J Virol 1988, 62:4232-4238.
2. Chanock RM, Kim HW, Vargosko AJ, Deleva A, Johnson KM, Cumming C, Parrot RH: Respiratory syncytial virus: I. Virus recovery and other observations during 1960 outbreak of bronchiolitis, pneumonia, and minor respiratory diseases in children. JAMA 1961, 176:647-653.
3. Parrott RH, Vargosko AJ, Kim HW, Cumming C, Turner H, Huebner RJ, Chanock RM: Respiratory syncytial virus. II. Serologic studies over a 34-month period of children with bronchiolitis, pneumonia, and minor respiratory diseases. JAMA 1961, 176:653-657.
4. Prober CG, Wang EE: Reducing the morbidity of lower respiratory tract infections caused by respiratory syncytial virus: still no answer. Pediatrics 1997, 99:454-61.
5. Simoes EAF, Rieger CHL: RSV infection in developed and developing countries. Infect Med 1999, 16:11-17.
6. Parrott RH, Kim HW, Arrobio JO, Hodes DS, Murphy BR, Brandt CD, Camargo E, Chanock RM: Epidemiology of respiratory syncytial virus infection in Washington D.C. II. Infection and disease with respect to age, immunological status, race and sex. J Epidemiol 1973, 98:289-300.
7. Levin MJ: Treatment and prevention options for respiratory syncytial virus infections. J Pediatrics 1994, 125:S22-S27.
8. Groothuis JR, Levin NJ, Rodriguez W, Hall CB, Long CE, Kim HW, Lauer BA, Hemming VG: Use of intravenous gamma globulin to passively immunize high-risk children against RSV: safety and pharmacokinetics. Antimicrob Agents Chemother 1991, 35(7):1469-1473.
9. Meissner HC, Fulton DR, Groothuis JR, Geggel RL, Marx GR, Hemming VG, Hougen T, Snydman DR: Controlled trial to evaluate protection of high-risk infants against RSV disease by using standard intravenous immune globulin. Antimicrob Agents Chemother 1993, 37:1655-1658.
10. MedImmune Inc: RespiGam™: Respiratory Syncytial Virus Immune Globulin Intravenous (Human), [RSV-IGIV]. Gaithersburg, MD 1996.
11. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531-537.
12. Cohen AH, Sorrentino M, Powers T: Effectiveness of palivizumab for preventing serious RSV disease. J Resp Dis 2000, 2:S30-S32.
13. MedImmune Inc: Synagis™: Palivizumab for intramuscular administration. Gaithersburg, MD 1996.
14. Arruda E, Pitkaranta A, Witek TJ Jr, Doyle CA, Hayden FG: Frequency and natural history of rhinovirus infections in adults during autumn. J Clin Microb 1997, 35:2864-2868.
15. Stanway G: Rhinoviruses. In: Webster RG ed. In Encyclopedia of Virology New York: Academic Press; 1994:1253-1259.
16. Skern T, Duechler M, Sommergruber W, Blaas D, Kuechler E: The molecular biology of human rhinoviruses. Biochem Soc Symp 1987, 53:63-73.
17. Staunton DE, Merluzzi VJ, Rothlein R, Barton R, Marlin SD, Springer TA: A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses. Cel 1989, 56:849-853.
18. Uncapher CR, Dewitt CM, Colonno RJ: The major and minor group receptor families contain all but one human rhinovirus serotype. Virology 1991, 180:814-817.
19. Marlin SD, Ltaunton DE, Springer TA: A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection. Nature 1990, 344:70-72.
20. Huguenel ED, Cohn D, Dockum DP, Greve JM, Fournel MA, Hammond L, Irwin R, Mahoney J, McClelland A, Muchmore E, Ohlin AC, Scuderi P: Prevention of rhinovirus infection in chimpanzees by soluble intercellular adhesion molecule-1. Am J Resp Critical Care Med 1997, 155:1206-1210.
21. Colonno RJ, Callahan PL, Long WJ: Isolation of a monoclonal antibody that blocks attachment of the major group of human rhinoviruses. J Virol 1986, 57:7-12.
22. Turner RB, Wecker MT, Pohl G, Witek TJ, McNally E, St George R, Winther B, Hayden FG: Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial. JAMA 1999, 281:1797-1804.
23. Colonno RJ: Virus receptors: the Achilles' heel of human rhinoviruses. Adv Exp Med Biol 1992, 312:61-70.
24. Hayden FG, Gwaltney JM, Colonno RJ: Modification of experimental rhinovirus colds by receptor blockade. Antiviral Res 1988, 9:233-247.
25. Casasnovas JM, Springer TA: Kinetics and thermodynamics of virus binding to receptor. Studies with rhinovirus, intercellular adhesion molecule-1 (ICAM-1), and surface plasmon resonance. J Biol Chem 1995, 270:13216-13224.
26. Charles CH, Luo GX, Kohlstaedt LA, Gorfain E, Morantte I, Williams JH, Fang F: Prevention of Human Rhinovirus Infection by Multivalent Fab Molecules Directed against ICAM-1. Antimicrobial Agents and Chemotherapy 2003, 47:1503-1508.
27. Luo GX, Kohlstaedt LA, Charles CH, Gorfain E, Morantte I, Williams JH, Fang F: Humanization of an anti-ICAM-1 antibody with over 50-fold affinity and functional improvement. J Immunol Methods 2003, 275:31-40.
28. Zamecnik PC, Stephenson ML: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978, 75:280-284.
29. Orr RM: Technology evaluation: fomivirsen. Isis Pharmaceuticals Inc/CIBA vision. Curr Opin Mol Ther 2001, 3:288-294.
30. Roehr B: Fomivirsen approved for CMV retinitis. J Int Assoc Physicians AIDS Care 1998, 4:14-16.
31. Dove A: Antisense and sensibility. Nat Biotechnol 2002, 20:121-124.
32. Braasch DA, Corey DR: Novel antisense and peptide nucleic acid strategies for controlling gene expression. Biochemistry 2002, 41:4503-4509.
33. Opalinska JB, Gewirtz AM: Nucleic acids therapeutics: Basic principles and recent applications. Nat Rev Drug Discov 2002, 1:503-514.
34. Kurreck J: Antisense technologies: Improvement through novel chemical modifications. Eur J Biochem 2003, 270:1628-1644.
35. Yu M, Ojwang J, Yamada O, Hampel A, Rappaport J, Looney D, Wong-Staal F: A Hairpin Ribozyme Inhibits Expression of Diverse Strains of HIV-1. Proc Natl Acad Sci USA 1993, 90:6341.
36. Welch P, Tritz R, Yei S, Barber JR, Yu M: Intracellular Application of Hairpin Ribozyme Genes Against Hepatitis B Virus. Gene Therapy 1997, 4:736.
37. Welch PJ, Tritz R, Yei S, Leavitt M, Yu M, Barber J: Apotential therapeutic application of hairpin ribozymes: In vitro and in vivo studies of gene therapy for hepatitis C virus infection. Gene Ther 1996, 3:994.
38. Tang XB, Hobom G, Luo D: Ribozyme mediated destruction of influenza A virus in vitro and in vivo. J Med Virol 1994, 42:385.
39. Macejak D, Jensen KL, Jamison S, Domenico K, Roberts EC, Chaudhary N, von Carlowitz I, Bellon L, Tong MJ, Conrad A, Pavco PA, Blatt LM: Inhibition of Hepatitis C Virus (HCV)-RNA-dependent translation and replication of a chimeric HCV Poliovirus using synthetic stabilized ribozymes. Hepatology 2000, 31:769-776.
40. McManus MT, Sharp PA: Gene silencing in mammals by small interfering RNAs. Nature Rev 2002, 3:737-747.
41. Thompson JD: Applications of antisense and siRNAs during preclinical drug development. Drug Discovery Today 2002, 7:912-917.
42. Shi Y: Mammalian RNAi for the masses. Trends in Genetics 2003,19:9-12.
43. Bitko V, Barik S: Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. BMC Microbiology 2001, 1:34-46.
44. Ge O, McManus MT, Nguyen T, Shen CH, Sharp PA, Eisen HN: RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc Natl Acad Sci USA 2003, 100:2718-2723.
45. Gitlin L, Karelsky S, Andino R: Short interfering RNA confers intracellular antiviral immunity in human cells. Nature 2002, 418:430-434.
46. Coburn GA, Cullen BR: Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. Journal of Virology 2002, 76:9225-9231.
47. Jacque JM, Triques K, Stevenson M: Modulation of HIV-1 replication by RNA interference. Nature 2002, 418:435-438.
48. Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK, Collman RG, Lieberman J, Shankar P, Sharp PA: siRNA-directed inhibition of HIV-1 infection. Nature Medicine 2002, 8:681-686.
49. Garrus JE, von Schwedler UK, Pornillos OW, Morham SG, Zavitz KH, Wang HE, Wettstein DA, Stray KM, Cote M, Rich RL, Myszka DG, Sundquist WI: Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 2001, 107:55-65.
50. Martinez MA, Gutierrez A, Armand-Ugon M, Blanco J, Parera M, Gomez J, Clotet B, Este JA: Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 2002, 16:2385-2390.
51. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF: Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997, 176:1215-1224.